Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York from September 3-5, 2025. The company's CEO, Daniel Passeri, will present on September 5, 2025, at 8:00 a.m. EDT.

During the presentation, the company will discuss updates on their Immuno-STAT® platform and the development progress of CUE-401, their primary autoimmune treatment candidate. The presentation will be available via webcast and archived for 30 days on the company's website.

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025.

During the fireside chat, Cue Biopharma will discuss program updates from the Immuno-STAT^® platform including continued advancements in the development of CUE-401, the Company’s lead autoimmune asset.

Presentation Details
Cantor Global Healthcare Conference
Date: Friday, September 5, 2025
Time: 8:00 a.m. – 8:30 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link: https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=15390931

A live and archived webcast of the fireside chat will be available under News and Events in the News and Publications section of the Company’s website. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT^® (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.

For more information, please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com

FAQ

When is Cue Biopharma (CUE) presenting at the Cantor Global Healthcare Conference 2025?

Cue Biopharma will present on Friday, September 5, 2025, from 8:00 a.m. to 8:30 a.m. EDT at the Cantor Global Healthcare Conference in New York.

Who will be presenting for Cue Biopharma at the Cantor Conference?

Daniel Passeri, Chief Executive Officer of Cue Biopharma, will be presenting at the conference.

What topics will Cue Biopharma discuss during their Cantor Conference presentation?

The company will discuss program updates from their Immuno-STAT® platform and development progress of CUE-401, their lead autoimmune asset.

How can investors access Cue Biopharma's Cantor Conference presentation?

Investors can access the presentation through a live webcast available under News and Events in the News and Publications section of the company's website. The webcast will be archived for 30 days.